The influence of ustekinumab on expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in patients with psoriasis and in a control

The aim of this study was to assess changes in the expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in psoriatic patients under ustekinumab treatment and in healthy volunteers. The study group consisted of 14 patients suffering from psoriasis vulgaris qualified for ustekinumab therapy (4 women, 10...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Dermatologic therapy Ročník 32; číslo 5; s. e13029 - n/a
Hlavní autori: Grabarek, Beniamin, Krzaczyński, Jakub, Strzałka‐Mrozik, Barbara, Wcisło‐Dziadecka, Dominika, Gola, Joanna
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Hoboken, USA John Wiley & Sons, Inc 01.09.2019
Predmet:
Adult
Dermatologic Agents - pharmacology
Female
Gene Expression Regulation - drug effects
Humans
Interleukin-17 - biosynthesis
Interleukin-17 - genetics
JAK/STAT signaling pathway
Male
Middle Aged
psoriasis
Psoriasis - drug therapy
Psoriasis - genetics
Psoriasis - metabolism
RNA - genetics
Signal Transduction
STAT1 Transcription Factor - biosynthesis
STAT1 Transcription Factor - genetics
STAT3 Transcription Factor - genetics
STAT4 Transcription Factor - biosynthesis
STAT4 Transcription Factor - genetics
Suppressor of Cytokine Signaling Proteins - biosynthesis
Suppressor of Cytokine Signaling Proteins - genetics
ustekinumab
Ustekinumab - pharmacology
Young Adult
psoriasis
JAK/STAT signaling pathway
ustekinumab
ISSN:1396-0296, 1529-8019, 1529-8019
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract The aim of this study was to assess changes in the expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in psoriatic patients under ustekinumab treatment and in healthy volunteers. The study group consisted of 14 patients suffering from psoriasis vulgaris qualified for ustekinumab therapy (4 women, 10 men) The control group consisted of 14 healthy volunteers (7 women, 7 men), their whole blood was used as a material in this study. A quantitative reverse transcription polymerase chain assay was used to amplify analyzed genes. To indicate the differences in expression of selected genes in the test and control groups, the Kruskal–Wallis and the post hoc Dunn's test was carried out. After 40 weeks of observation of the effectiveness of ustekinumab in patients with psoriasis, the expression of STAT1, STAT3, STAT4, IL17, and SOCS2 was silenced. Statistic differences in expression were observed for STAT3 (40 vs. 0 weeks, p < .05; 0 week vs. C, p < .05) and SOCS2 (0 week vs. C, p < .05). Patients with psoriasis vulgaris have higher levels of STAT1, STAT3, STAT4, SOCS2, and IL17 expression compared to healthy individuals. On the other hand, the treatment of ustekinumab lasting 40 weeks caused a decrease in the transcriptional activity of the analyzed genes.
AbstractList The aim of this study was to assess changes in the expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in psoriatic patients under ustekinumab treatment and in healthy volunteers. The study group consisted of 14 patients suffering from psoriasis vulgaris qualified for ustekinumab therapy (4 women, 10 men) The control group consisted of 14 healthy volunteers (7 women, 7 men), their whole blood was used as a material in this study. A quantitative reverse transcription polymerase chain assay was used to amplify analyzed genes. To indicate the differences in expression of selected genes in the test and control groups, the Kruskal-Wallis and the post hoc Dunn's test was carried out. After 40 weeks of observation of the effectiveness of ustekinumab in patients with psoriasis, the expression of STAT1, STAT3, STAT4, IL17, and SOCS2 was silenced. Statistic differences in expression were observed for STAT3 (40 vs. 0 weeks, p < .05; 0 week vs. C, p < .05) and SOCS2 (0 week vs. C, p < .05). Patients with psoriasis vulgaris have higher levels of STAT1, STAT3, STAT4, SOCS2, and IL17 expression compared to healthy individuals. On the other hand, the treatment of ustekinumab lasting 40 weeks caused a decrease in the transcriptional activity of the analyzed genes.
The aim of this study was to assess changes in the expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in psoriatic patients under ustekinumab treatment and in healthy volunteers. The study group consisted of 14 patients suffering from psoriasis vulgaris qualified for ustekinumab therapy (4 women, 10 men) The control group consisted of 14 healthy volunteers (7 women, 7 men), their whole blood was used as a material in this study. A quantitative reverse transcription polymerase chain assay was used to amplify analyzed genes. To indicate the differences in expression of selected genes in the test and control groups, the Kruskal-Wallis and the post hoc Dunn's test was carried out. After 40 weeks of observation of the effectiveness of ustekinumab in patients with psoriasis, the expression of STAT1, STAT3, STAT4, IL17, and SOCS2 was silenced. Statistic differences in expression were observed for STAT3 (40 vs. 0 weeks, p < .05; 0 week vs. C, p < .05) and SOCS2 (0 week vs. C, p < .05). Patients with psoriasis vulgaris have higher levels of STAT1, STAT3, STAT4, SOCS2, and IL17 expression compared to healthy individuals. On the other hand, the treatment of ustekinumab lasting 40 weeks caused a decrease in the transcriptional activity of the analyzed genes.The aim of this study was to assess changes in the expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in psoriatic patients under ustekinumab treatment and in healthy volunteers. The study group consisted of 14 patients suffering from psoriasis vulgaris qualified for ustekinumab therapy (4 women, 10 men) The control group consisted of 14 healthy volunteers (7 women, 7 men), their whole blood was used as a material in this study. A quantitative reverse transcription polymerase chain assay was used to amplify analyzed genes. To indicate the differences in expression of selected genes in the test and control groups, the Kruskal-Wallis and the post hoc Dunn's test was carried out. After 40 weeks of observation of the effectiveness of ustekinumab in patients with psoriasis, the expression of STAT1, STAT3, STAT4, IL17, and SOCS2 was silenced. Statistic differences in expression were observed for STAT3 (40 vs. 0 weeks, p < .05; 0 week vs. C, p < .05) and SOCS2 (0 week vs. C, p < .05). Patients with psoriasis vulgaris have higher levels of STAT1, STAT3, STAT4, SOCS2, and IL17 expression compared to healthy individuals. On the other hand, the treatment of ustekinumab lasting 40 weeks caused a decrease in the transcriptional activity of the analyzed genes.
Author Wcisło‐Dziadecka, Dominika
Strzałka‐Mrozik, Barbara
Krzaczyński, Jakub
Gola, Joanna
Grabarek, Beniamin
Author_xml – sequence: 1
  givenname: Beniamin
  orcidid: 0000-0003-1633-7145
  surname: Grabarek
  fullname: Grabarek, Beniamin
  email: bgrabarek7@gmail.com
  organization: Medical University of Silesia in Katowice
– sequence: 2
  givenname: Jakub
  surname: Krzaczyński
  fullname: Krzaczyński, Jakub
  organization: Medical University of Silesia in Katowice
– sequence: 3
  givenname: Barbara
  surname: Strzałka‐Mrozik
  fullname: Strzałka‐Mrozik, Barbara
  organization: Medical University of Silesia in Katowice
– sequence: 4
  givenname: Dominika
  orcidid: 0000-0003-0501-7592
  surname: Wcisło‐Dziadecka
  fullname: Wcisło‐Dziadecka, Dominika
  organization: Medical University of Silesia in Katowice
– sequence: 5
  givenname: Joanna
  surname: Gola
  fullname: Gola, Joanna
  organization: Medical University of Silesia in Katowice
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31330078$$D View this record in MEDLINE/PubMed
BookMark eNp1kU1LxDAQhoMofh_8A5KjgtVMsv3IUdZPWPBgPYc0nbLRblKbFvXibzfurhfRXN4h88wLM-8e2XTeISFHwM4hvot6mJ-DYFxukF1IuUwKBnIz1kJmSfzOdsheCM-MAZcCtsmOACEYy4td8lnOkVrXtCM6g9Q3dAwDvlg3LnRFvaP43vUYgo1lbD6WlyWcLUWsZBLlYfrIz6h2Nb2fQR7taKcHi24I9M0Oc9oF31sdbFgysa2p8W7ofXtAthrdBjxc6z55urkup3fJ7OH2fno5S4zgqUyyJjd8YgrJM6w1q9IKaywmVZaKLK9kWoNBXjUpmxQcRQXAUHANPE0FxFPkYp-crHy73r-OGAa1sMFg22qHfgyK8yzPZSagiOjxGh2rBdaq6-1C9x_q52YRuFgBpvch9NgoY4e47_dG2rYKmPpORcVU1DKVOHH6a-LH9C927f5mW_z4H1RX5d1q4gviY5gn
CitedBy_id crossref_primary_10_4103_ijd_ijd_10_21
crossref_primary_10_1371_journal_pone_0317666
crossref_primary_10_3390_ijms232415855
crossref_primary_10_1016_j_biteb_2024_101844
crossref_primary_10_1111_dth_13141
Cites_doi 10.1136/gutjnl-2019-318448
10.1016/j.pharmthera.2018.07.003
10.1007/s00018-003-3228-z
10.1111/dth.12843
10.1016/j.clim.2016.09.014
10.3899/jrheum.150636
10.1084/jem.20170369
10.1002/pro.3519
10.1007/s10238-008-0006-0
10.4049/jimmunol.1800013
10.1053/j.gastro.2018.01.043
10.2174/187152812800392805
10.1016/j.jaci.2009.08.046
10.1007/s12016-018-8702-3
10.1016/j.jval.2013.08.2293
10.1016/j.jaci.2012.04.024
10.1111/dth.12793
10.5114/ada.2018.77665
10.1111/1346-8138.13987
10.1016/j.tips.2019.03.001
10.1038/ni.3790
10.1371/journal.pone.0090284
10.2165/11207530-000000000-00000
10.1016/j.bbrc.2018.05.042
10.1155/MI.2005.273
10.1038/jid.2011.222
10.1016/j.intimp.2018.06.020
10.1136/jim-2016-000176
10.4049/jimmunol.1001001
10.1038/gene.2014.64
ContentType Journal Article
Copyright 2019 Wiley Periodicals, Inc.
Copyright_xml – notice: 2019 Wiley Periodicals, Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1111/dth.13029
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1529-8019
EndPage n/a
ExternalDocumentID 31330078
10_1111_dth_13029
DTH13029
Genre article
Journal Article
GrantInformation_xml – fundername: Consent of the Bioethics Commission of Medical University of Silesia
  funderid: KNW/0022/KB1/59/I/13/14
– fundername: Medical University of Silesia
  funderid: KNW‐1‐032/N/9/I
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
1OC
24P
29F
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAJEY
AAKAS
AANHP
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABPVW
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCMX
ACCZN
ACGFS
ACMXC
ACPOU
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEIMD
AENEX
AEQDE
AEUQT
AFBPY
AFEBI
AFGKR
AFPWT
AFZJQ
AIACR
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
H.X
H13
HF~
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
RHX
ROL
RX1
SUPJJ
SV3
TEORI
TUS
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
XG1
YFH
ZZTAW
~IA
~WT
7X7
8FI
8FJ
AAFWJ
AAMMB
AAYXX
ABUWG
AEFGJ
AFFHD
AFKRA
AGQPQ
AGXDD
AIDQK
AIDYY
BENPR
CCPQU
CITATION
FYUFA
HMCUK
O8X
PHGZM
PHGZT
PIMPY
UKHRP
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c3259-6f7c24c8926eda0b5bede84b65367b95d1ce2bf50482e3b110e32a12553101973
IEDL.DBID DRFUL
ISICitedReferencesCount 7
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000478137600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1396-0296
1529-8019
IngestDate Wed Oct 01 12:56:28 EDT 2025
Wed Feb 19 02:30:48 EST 2025
Sat Nov 29 06:19:06 EST 2025
Tue Nov 18 22:33:15 EST 2025
Wed Jan 22 16:39:33 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords psoriasis
JAK/STAT signaling pathway
ustekinumab
Language English
License 2019 Wiley Periodicals, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3259-6f7c24c8926eda0b5bede84b65367b95d1ce2bf50482e3b110e32a12553101973
Notes Funding information
Consent of the Bioethics Commission of Medical University of Silesia, Grant/Award Number: KNW/0022/KB1/59/I/13/14; Medical University of Silesia, Grant/Award Number: KNW‐1‐032/N/9/I
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-0501-7592
0000-0003-1633-7145
PMID 31330078
PQID 2267796318
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_2267796318
pubmed_primary_31330078
crossref_citationtrail_10_1111_dth_13029
crossref_primary_10_1111_dth_13029
wiley_primary_10_1111_dth_13029_DTH13029
PublicationCentury 2000
PublicationDate September/October 2019
2019-09-00
20190901
PublicationDateYYYYMMDD 2019-09-01
PublicationDate_xml – month: 09
  year: 2019
  text: September/October 2019
PublicationDecade 2010
PublicationPlace Hoboken, USA
PublicationPlace_xml – name: Hoboken, USA
– name: United States
PublicationTitle Dermatologic therapy
PublicationTitleAlternate Dermatol Ther
PublicationYear 2019
Publisher John Wiley & Sons, Inc
Publisher_xml – name: John Wiley & Sons, Inc
References 2004; 61
2015; 16
2015; 93
2018; 501
2018; 105
2019; 32
2017; 44
2018; 201
2017; 65
2018; 1052
2018; 189
2008; 8
2018; 62
2012; 11
2005; 2005
2018; 27
2011; 131
2012; 130
2018; 154
2018; 2
2018; 192
2019; 40
2013; 16
2018; 215
2011; 71
2019
2009; 124
2017; 18
2014; 9
2018; 55
2018; 35
2011; 186
e_1_2_8_28_1
e_1_2_8_29_1
e_1_2_8_24_1
e_1_2_8_25_1
e_1_2_8_26_1
e_1_2_8_27_1
Reich A. (e_1_2_8_22_1) 2018; 1052
e_1_2_8_3_1
Felis‐Giemza A. (e_1_2_8_14_1) 2018; 2
e_1_2_8_2_1
Reich A. (e_1_2_8_23_1) 2018; 105
e_1_2_8_5_1
e_1_2_8_4_1
e_1_2_8_7_1
e_1_2_8_6_1
e_1_2_8_9_1
e_1_2_8_8_1
e_1_2_8_20_1
e_1_2_8_21_1
e_1_2_8_17_1
e_1_2_8_18_1
e_1_2_8_19_1
e_1_2_8_13_1
e_1_2_8_15_1
e_1_2_8_16_1
e_1_2_8_32_1
e_1_2_8_10_1
e_1_2_8_31_1
e_1_2_8_11_1
e_1_2_8_34_1
e_1_2_8_12_1
e_1_2_8_33_1
e_1_2_8_30_1
References_xml – volume: 9
  year: 2014
  article-title: IL‐17 induces an expanded range of downstream genes in reconstituted human epidermis model
  publication-title: PLoS One
– volume: 192
  start-page: 100
  year: 2018
  end-page: 111
  article-title: Targeting JAK‐STAT signal transduction in IBD
  publication-title: Pharmacology & Therapeutic
– volume: 62
  start-page: 46
  year: 2018
  end-page: 58
  article-title: Efficacy and safety of biologics targeting IL‐17 and IL‐23 in the treatment of moderate‐to‐severe plaque psoriasis: A systematic review and meta‐analysis of randomized controlled trials
  publication-title: International Immunopharmacology
– volume: 186
  start-page: 1495
  year: 2011
  end-page: 1502
  article-title: IL‐23‐mediated psoriasis‐like epidermal hyperplasia is dependent on IL‐17A
  publication-title: Journal of Immunology
– volume: 2005
  start-page: 273
  issue: 5
  year: 2005
  end-page: 279
  article-title: Serum levels of TNF‐α, IFN‐γ, IL‐6, IL‐8, IL‐12, IL‐17, and IL‐18 in patients with active psoriasis and correlation with disease severity
  publication-title: Mediators of Inflammation
– volume: 65
  start-page: 376
  issue: 2
  year: 2017
  end-page: 381
  article-title: Calcipotriol inhibits proliferation of human keratinocytes by downregulating STAT1 and STAT3 signaling
  publication-title: Journal of Investigative Medicine
– volume: 27
  start-page: 1984
  issue: 12
  year: 2018
  end-page: 2009
  article-title: The molecular details of cytokine signaling via the JAK/STAT pathway
  publication-title: Protein Science
– volume: 16
  start-page: 170
  issue: 2
  year: 2015
  end-page: 175
  article-title: Activation of the JAK/STAT pathway in Behcet's disease
  publication-title: Genes and Immunity
– year: 2019
  article-title: JAK selectivity for inflammatory bowel disease treatment: Does it clinically matter?
  publication-title: Gut
– volume: 189
  start-page: 4
  year: 2018
  end-page: 13
  article-title: Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases
  publication-title: Clinical Immunology
– volume: 44
  start-page: 1380
  issue: 12
  year: 2017
  end-page: 1384
  article-title: New onset or transition of disease state of psoriatic arthritis during treatment with ustekinumab: A single‐center retrospective study
  publication-title: The Journal of Dermatology
– volume: 35
  start-page: 360
  issue: 4
  year: 2018
  end-page: 366
  article-title: The level of proinflammatory cytokines: Interleukins 12, 23, 17 and tumor necrosis factor α in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis
  publication-title: Advances in Dermatology and Allergology
– volume: 93
  start-page: 48
  year: 2015
  end-page: 52
  article-title: Ex vivo signaling protein mapping in T lymphocytes in the psoriatic arthritis joints
  publication-title: The Journal of Rheumatology Supplement
– volume: 61
  start-page: 567
  year: 2004
  end-page: 579
  article-title: Interleukin‐17: A mediator of inflammatory responses
  publication-title: Cellular and Molecular Life Sciences
– volume: 18
  start-page: 826
  issue: 8
  year: 2017
  end-page: 831
  article-title: A guiding map for inflammation
  publication-title: Nature Immunology
– volume: 215
  start-page: 1079
  year: 2018
  end-page: 1090
  article-title: STAT‐3‐independent production of IL‐17 by mouse innate‐like alphaβ T cells controls ocular infection
  publication-title: The Journal of Experimental Medicine
– volume: 1052
  start-page: 225
  year: 2018
  end-page: 243
  article-title: Psoriasis. Diagnostic and therapeutic recommendations of the polish dermatological society. Part I: Mild psoriasis
  publication-title: Dermatology Review/Przeglad Dermatologiczny
– volume: 11
  start-page: 159
  issue: 2
  year: 2012
  end-page: 168
  article-title: The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases
  publication-title: Inflammation and Allergy Drug Targets
– volume: 131
  start-page: 2401
  issue: 12
  year: 2011
  end-page: 2408
  article-title: IL‐17A upregulates keratin 17 expression in keratinocytes through STAT1‐and STAT3‐dependent mechanisms
  publication-title: The Journal of Investigative Dermatology.
– volume: 8
  start-page: 179
  year: 2008
  end-page: 185
  article-title: The analysis of CIS, SOCS1, SOSC2 and SOCS3 transcript levels in peripheral blood mononuclear cells of systemic lupus erythematosus and rheumatoid arthritis patients
  publication-title: Clinical and Experimental Medicine
– volume: 16
  start-page: 1150
  issue: 8
  year: 2013
  end-page: 1155
  article-title: Assessment of PRO label claims granted by the FDA as compared to the EMA (2006–2010)
  publication-title: Value in Health
– volume: 501
  start-page: 563
  issue: 2
  year: 2018
  end-page: 569
  article-title: STAT1 activation represses IL‐22 gene expression and psoriasis pathogenesis
  publication-title: Biochemical and Biophysical Research Communications
– volume: 124
  start-page: 1022
  year: 2009
  end-page: 10.e1‐395
  article-title: Effective treatment of psoriasis with etanercept is linked to suppression of IL‐17 signaling, not immediate response TNF genes
  publication-title: Journal of Allergy and Clinical Immunology
– volume: 2
  start-page: 168
  issue: 2
  year: 2018
  end-page: 172
  article-title: Przygotowanie pacjenta reumatologicznego do leczenia biologicznego—na co należy zwrócić uwagę
  publication-title: Varia Medica
– volume: 105
  start-page: 329
  issue: 3
  year: 2018
  end-page: 357
  article-title: Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part II: Moderate to severe psoriasis
  publication-title: Dermatology Review/Przegląd Dermatologiczny
– volume: 154
  start-page: 1660
  issue: 6
  year: 2018
  end-page: 1671
  article-title: Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's disease
  publication-title: Gastroenterology
– volume: 201
  start-page: 1605
  issue: 6
  year: 2018
  end-page: 1613
  article-title: Discovery of the IL‐23/IL‐17 signaling pathway and the treatment of psoriasis
  publication-title: The Journal of Immunology
– volume: 32
  year: 2019
  article-title: The analysis of the therapeutic potential of ustekinumab in psoriasis vulgaris treatment
  publication-title: Dermatologic Therapy
– volume: 40
  start-page: 299
  issue: 5
  year: 2019
  end-page: 308
  article-title: Targeting SOCS proteins to control JAK‐STAT signalling in disease
  publication-title: Trends in Pharmacological Sciences
– volume: 55
  start-page: 379
  issue: 3
  year: 2018
  end-page: 390
  article-title: The immunologic role of IL‐17 in psoriasis and psoriatic arthritis pathogenesis
  publication-title: Clinical Reviews in Allergy & Immunology
– volume: 71
  start-page: 1733
  issue: 13
  year: 2011
  end-page: 1753
  article-title: Ustekinumab
  publication-title: Drugs
– volume: 32
  issue: 2
  year: 2019
  article-title: When IL‐17 inhibitors fail: Real‐life evidence to switch from secukinumab to adalimumab or ustekinumab
  publication-title: Dermatologic Therapy
– volume: 130
  start-page: 145
  year: 2012
  end-page: 154
  article-title: IL‐17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
  publication-title: The Journal of Allergy and Clinical Immunology
– ident: e_1_2_8_11_1
  doi: 10.1136/gutjnl-2019-318448
– ident: e_1_2_8_26_1
  doi: 10.1016/j.pharmthera.2018.07.003
– ident: e_1_2_8_32_1
  doi: 10.1007/s00018-003-3228-z
– ident: e_1_2_8_31_1
  doi: 10.1111/dth.12843
– ident: e_1_2_8_33_1
  doi: 10.1016/j.clim.2016.09.014
– volume: 1052
  start-page: 225
  year: 2018
  ident: e_1_2_8_22_1
  article-title: Psoriasis. Diagnostic and therapeutic recommendations of the polish dermatological society. Part I: Mild psoriasis
  publication-title: Dermatology Review/Przeglad Dermatologiczny
– ident: e_1_2_8_15_1
  doi: 10.3899/jrheum.150636
– ident: e_1_2_8_27_1
  doi: 10.1084/jem.20170369
– ident: e_1_2_8_19_1
  doi: 10.1002/pro.3519
– ident: e_1_2_8_29_1
  doi: 10.1007/s10238-008-0006-0
– ident: e_1_2_8_16_1
  doi: 10.4049/jimmunol.1800013
– ident: e_1_2_8_2_1
  doi: 10.1053/j.gastro.2018.01.043
– ident: e_1_2_8_28_1
  doi: 10.2174/187152812800392805
– ident: e_1_2_8_34_1
  doi: 10.1016/j.jaci.2009.08.046
– ident: e_1_2_8_6_1
  doi: 10.1007/s12016-018-8702-3
– ident: e_1_2_8_12_1
  doi: 10.1016/j.jval.2013.08.2293
– ident: e_1_2_8_17_1
  doi: 10.1016/j.jaci.2012.04.024
– ident: e_1_2_8_10_1
  doi: 10.1111/dth.12793
– ident: e_1_2_8_21_1
  doi: 10.5114/ada.2018.77665
– ident: e_1_2_8_4_1
  doi: 10.1111/1346-8138.13987
– ident: e_1_2_8_13_1
  doi: 10.1016/j.tips.2019.03.001
– ident: e_1_2_8_20_1
  doi: 10.1038/ni.3790
– volume: 105
  start-page: 329
  issue: 3
  year: 2018
  ident: e_1_2_8_23_1
  article-title: Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part II: Moderate to severe psoriasis
  publication-title: Dermatology Review/Przegląd Dermatologiczny
– ident: e_1_2_8_7_1
  doi: 10.1371/journal.pone.0090284
– ident: e_1_2_8_8_1
  doi: 10.2165/11207530-000000000-00000
– ident: e_1_2_8_5_1
  doi: 10.1016/j.bbrc.2018.05.042
– ident: e_1_2_8_3_1
  doi: 10.1155/MI.2005.273
– ident: e_1_2_8_25_1
  doi: 10.1038/jid.2011.222
– volume: 2
  start-page: 168
  issue: 2
  year: 2018
  ident: e_1_2_8_14_1
  article-title: Przygotowanie pacjenta reumatologicznego do leczenia biologicznego—na co należy zwrócić uwagę
  publication-title: Varia Medica
– ident: e_1_2_8_9_1
  doi: 10.1016/j.intimp.2018.06.020
– ident: e_1_2_8_18_1
  doi: 10.1136/jim-2016-000176
– ident: e_1_2_8_24_1
  doi: 10.4049/jimmunol.1001001
– ident: e_1_2_8_30_1
  doi: 10.1038/gene.2014.64
SSID ssj0012931
Score 2.2673593
Snippet The aim of this study was to assess changes in the expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in psoriatic patients under ustekinumab treatment and in...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e13029
SubjectTerms Adult
Dermatologic Agents - pharmacology
Female
Gene Expression Regulation - drug effects
Humans
Interleukin-17 - biosynthesis
Interleukin-17 - genetics
JAK/STAT signaling pathway
Male
Middle Aged
psoriasis
Psoriasis - drug therapy
Psoriasis - genetics
Psoriasis - metabolism
RNA - genetics
Signal Transduction
STAT1 Transcription Factor - biosynthesis
STAT1 Transcription Factor - genetics
STAT3 Transcription Factor - genetics
STAT4 Transcription Factor - biosynthesis
STAT4 Transcription Factor - genetics
Suppressor of Cytokine Signaling Proteins - biosynthesis
Suppressor of Cytokine Signaling Proteins - genetics
ustekinumab
Ustekinumab - pharmacology
Young Adult
Title The influence of ustekinumab on expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in patients with psoriasis and in a control
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fdth.13029
https://www.ncbi.nlm.nih.gov/pubmed/31330078
https://www.proquest.com/docview/2267796318
Volume 32
WOSCitedRecordID wos000478137600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library Full Collection 2020
  customDbUrl:
  eissn: 1529-8019
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0012931
  issn: 1396-0296
  databaseCode: DRFUL
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Na9swFH80aRm7rF23dVnboJUedoghlmzLpqfSNmSQdaV1IDcjyTILW-1SJ2On_e17kmXT0g4GO8mgJyH0vn6Snt8DOA5RcANGkQMxp14gxtyTaiy8UEWyiGKlZSBtsQl-eRkvFsnVBpy0_8I0-SG6CzejGdZeGwUXsn6g5PnqmyllTJMebFKU27APm-fXk_mse0RAT9act2ycbRK5xEImkKcb_NgdPcGYjyGr9TmT7f9a7Q68clCTnDay8Ro2dLkLL764x_Q38BtFhCzbIiWkKsgaWf59Wa5vhSRVSfQvFyVbms6b9DT1R7ZhTRNg8_Xsho6IKHPyeeZznI64TK01MVe85K6uUMTrZW1psFsQFx3_FuaTi_Rs6rlyDJ5ieEjyooIrGqg4oZHOxViGUuc6DmQUsojLJMx9paksQrQJVDOJuEIzKhBAoZojkOTsHfTLqtTvgYRSjAuG49HgmBJoiUTgIzlDtKjRW-oBfGq5kimXq9yUzPiRtWcW3M_M7ucAjjrSuyZBx3NEH1vWZqg-5k1ElLpa1xmiT87RCPnxAPYannfTMDy_GwiFq7Gs_fv82Xk6tR8f_p10H14i-HLxagfQX92v9SFsqZ-rZX0_hB5fxEMn0X8AYHDzcQ
linkProvider Wiley-Blackwell
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB5RQC0XHi2PBQqm6oEDkXbtJE4kLghYLWLZVhAkbpHtOGLVNkFkF3HitzN2nAhEkSr15EgeW5bn9dmezAB8D1BwfUaRAxGnni-63JOqK7xAhTIPI6WlL22xCT4aRTc38c8ZOGz-hanzQ7QXbkYzrL02Cm4upF9oeTa5NbWMafwB5nwUI5TvuZPL_vWwfUVAV1YfuGygbRy6zEImkqcd_NofvQGZrzGrdTr9pf9b7jIsOrBJjmrpWIEZXXyGjxfuOf0LPKGQkHFTpoSUOZki03-Ni-kfIUlZEP3o4mQL03mVHCW9A9uwuvGx-XF8RQ-IKDJyNuxxnI64XK0VMZe85K4qUcircWVpsFsQFx-_Ctf90-R44LmCDJ5ieEzywpwr6qsopqHORFcGUmc68mUYsJDLOMh6SlOZB2gVqGYSkYVmVCCEQkVHKMnZGswWZaE3gARSdHOG49HkmCJosUToIzlDvKjRX-oO7DdsSZXLVm6KZvxOm1ML7mdq97MD31rSuzpFx9-I9hrepqhA5lVEFLqcViniT87RDPWiDqzXTG-nYXiCNyAKV2N5-_786UkysB-b_066C58GycUwHZ6NzrdgAaGYi17bhtnJ_VR_hXn1MBlX9ztOsJ8BQ-r2eQ
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NT9swFH9iZUK7ABtjdDBmEAcORGrtJE4kLoiuAq0rCIrELbIdR1RAUjXttNP-dp4dJwIBEhInR_KzZfl9_Wy_vAewF6Dg-owiByJOPV90uCdVR3iBCmUWRkpLX9piE3w4jK6v4_MFOKz_hanyQzQXbkYzrL02Cq4nafZIy9PZjallTOMPsOibIjItWOxd9K8GzSsCurLqwGUDbePQZRYykTzN4Kf-6BnIfIpZrdPpr7xvuauw7MAmOaqk4zMs6PwLLP1xz-lr8B-FhIzrMiWkyMgcmX47zuf3QpIiJ_qfi5PNTefl6GjUPbANqxofm7PjS3pARJ6S00GX43TE5WotibnkJZOyQCEvx6WlwW5BXHz8V7jq_xodn3iuIIOnGB6TvDDjivoqimmoU9GRgdSpjnwZBizkMg7SrtJUZgFaBaqZRGShGRUIoVDREUpytg6tvMj1BpBAik7GcDyaHFMELZYIfSRniBc1-kvdhv2aLYly2cpN0Yy7pD614H4mdj_bsNuQTqoUHS8R7dS8TVCBzKuIyHUxLxPEn5yjGepGbfhWMb2ZhuEJ3oAoXI3l7evzJ73Rif34_nbSn7B03usng9Ph7034hEjMBa9tQWs2nesf8FH9nY3L6baT6wfbKPX0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+influence+of+ustekinumab+on+expression+of+STAT1+%2C+STAT3+%2C+STAT4+%2C+SOCS2+%2C+and+IL17+in+patients+with+psoriasis+and+in+a+control&rft.jtitle=Dermatologic+therapy&rft.au=Grabarek%2C+Beniamin&rft.au=Krzaczy%C5%84ski%2C+Jakub&rft.au=Strza%C5%82ka%E2%80%90Mrozik%2C+Barbara&rft.au=Wcis%C5%82o%E2%80%90Dziadecka%2C+Dominika&rft.date=2019-09-01&rft.issn=1396-0296&rft.eissn=1529-8019&rft.volume=32&rft.issue=5&rft_id=info:doi/10.1111%2Fdth.13029&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_dth_13029
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1396-0296&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1396-0296&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1396-0296&client=summon